Komodo Health's Real-World Evidence Platform Drives 31 Patient Journey Research Studies at ISPOR 2025

Comprehensive Patient Journey Data Links Clinical Outcomes to Real-World Impact, Addressing Critical Evidence Gaps in Oncology, Neurology, Cardiovascular, Metabolic, and Rare Diseases

MONTREAL--(BUSINESS WIRE)--Komodo Health today announced that its healthcare intelligence platform enabled 31 research studies being presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. These include three studies led by Komodo researchers and 27 collaborative studies with academic institutions, Life Sciences companies, and healthcare organizations.

"The volume and diversity of research powered by our healthcare insights underscore the growing demand for high-quality real-world data combined with advanced analytical capabilities," said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health. "By connecting individual patient journeys to large-scale health outcomes, we're enabling researchers to uncover actionable insights that improve clinical practice, healthcare policy, and patient outcomes."

The ISPOR 2025 research presentations demonstrate the value of Komodo's real-world evidence across a wide range of therapeutic areas, including:

• Oncology: Salix Pharmaceuticals, Analysis Group, and Bausch Health studied the economic burden of opioid-induced constipation among patients with or without cancer;
• Cardiovascular disease: Veradigm examined the discordance between apolipoprotein B and low-density lipoprotein cholesterol levels in predicting incident hypertension risk and how it correlates to differential hypertension development patterns between diabetic and non-diabetic populations;
• Metabolic disorders: Novo Nordisk studied non-invasive diagnostic approaches and earlier interventions for metabolic dysfunction-associated steatohepatitis (MASH);
• Neurology: Jazz Pharmaceuticals analyzed healthcare resource utilization and costs among individuals with narcolepsy or idiopathic hypersomnia (IH) who are considered at higher risk for negative clinical outcomes associated with sodium (due to underlying cardiovascular, cardiometabolic, or renal conditions); and
• Rare disease: Chiesi analyzed medical claims data to better understand healthcare resource utilization patterns among Fabry disease patients

Three poster presentations by Komodo researchers also showcase methodological advances:

• Sequential target trial emulation to assess mortality impact of amyotrophic lateral sclerosis treatments (CO79);
• Benchmarking injectable medication duration through claims interval vs. days supply analysis (SA31); and
• Expanding longitudinal patient data through tokenized linkage technology (RWD134)

Advancing Research Through Integrated Data Analytics

Komodo provides a multidimensional view of 330+ million patient journeys by linking de-identified claims data with specialty datasets, including lab results, genomics, and demographic information — through its platform to address fundamental challenges in health economics and outcomes research (HEOR). Whereas HEOR teams have traditionally relied on fragmented, incomplete datasets that provide only narrow snapshots of patients' in-network healthcare experiences, Komodo’s platform enables researchers to link disparate datasets without the months typically spent on data cleaning and integration. The option to enhance disease understanding at the patient level with lab, EHR, patient insurance, race and ethnicity, and mortality data enables teams to self-serve cohort feasibility and insights. This ability accelerates study planning timelines by weeks and generates more accurate estimates of treatment patterns, healthcare resource utilization, and costs.

"By closing critical data gaps and providing a patient-centric approach to HEOR, our powerful, all-in-one platform brings clean, connected, and compliant real-world data together," Nathoo added. "We eliminate the need for messy integrations, manual data wrangling, and coding cohorts from scratch, which enables HEOR teams to generate evidence faster. The inclusion of race, ethnicity, mortality, and other demographic insights at a near-census level also allows researchers to better model the clinical and financial impacts of new therapies across diverse populations, addressing the reality that disease burden is not borne equally across demographic groups."

Connect with Komodo at ISPOR 2025.

About Komodo Health

Komodo is a healthcare insights and technology company that delivers the Evidentiary Standard for real-world data and analytics. By pairing the industry’s most complete, unbiased view of patient encounters with AI-enabled and fit-for-purpose software, Komodo connects the dots between patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo delivers a velocity advantage by helping its customers accurately and efficiently access patient-centric insights at scale to drive faster decision-making, optimize workflows, close gaps in care, and help reduce the burden of disease. For more information, visit Komodohealth.com.